Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Operating Expenses: 2016-2023

Historic Other Operating Expenses for Zevra Therapeutics (ZVRA) over the last 7 years, with Dec 2023 value amounting to -$78.9 million.

  • Zevra Therapeutics' Other Operating Expenses was N/A to -$20.7 million in Q1 2024 from the same period last year, while for Mar 2024 it was -$70.6 million, marking a year-over-year change of. This contributed to the annual value of -$78.9 million for FY2023, which is 2.20% up from last year.
  • Zevra Therapeutics' Other Operating Expenses amounted to -$78.9 million in FY2023, which was up 2.20% from -$80.7 million recorded in FY2022.
  • Zevra Therapeutics' Other Operating Expenses' 5-year high stood at $2.9 million during FY2019, with a 5-year trough of -$80.7 million in FY2022.
  • Its 3-year average for Other Operating Expenses is -$52.5 million, with a median of -$78.9 million in 2023.
  • As far as peak fluctuations go, Zevra Therapeutics' Other Operating Expenses surged by 80.01% in 2019, and later slumped by 4,017.05% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Other Operating Expenses stood at $2.9 million in 2019, then decreased by 27.57% to $2.1 million in 2020, then fell by 3.47% to $2.1 million in 2021, then crashed by 4,017.05% to -$80.7 million in 2022, then increased by 2.20% to -$78.9 million in 2023.